Deals don’t just happen on their own. They happen by building, managing, and scaling relationships. At 4Degrees, we understand the immense value of relationships, so we build a platform that brings your network to life. The 4Degrees Relationship Intelligence CRM platform empowers relationship-focused professionals like you by identifying the right connections to focus on while helping you strengthen those relationships and activate your network when you need it. Whether you’re starting from spreadsheets or looking to level up from your existing systems, we’d love to help you and your team maximize your relationship network potential.

Acesion Pharma is a Danish biotech company founded in 2011. We are aiming to develop more efficacious and safer drugs for the treatment of Atrial Fibrillation (AF), the most common type of cardiac arrhythmia. The scientific foundation of Acesion Pharma is the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery, and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

AER Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on treating respiratory diseases with significant unmet need, such as COPD, Cystic Fibrosis, and Asthma. Our technology was developed and spun out of Dr. John Fahy’s Airway Biology Lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s Glycochemistry Lab at University College Dublin and Dr. Anne Marie Healy’s Pharmaceutics Lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.

Aeva’s mission is to bring the next wave of perception to a broad range of applications from automated driving to industrial robotics, consumer electronics, consumer health, security and beyond. Aeva is transforming autonomy with its groundbreaking sensing and perception technology that integrates all key lidar components onto a silicon photonics chip in a compact module. Aeva 4d lidar sensors uniquely detect instant velocity in addition to 3d position, allowing autonomous devices like vehicles and robots to make more intelligent and safe decisions.

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure, and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease-modifying potential in severe organ failure and fibrotic diseases.

AIM Security is the industry guide to secure GenAI adoption, equipping security leaders with the ability to drive business productivity while providing the right guardrails and ensuring proactive protection for all use cases across the entire organization, whether enterprise use or production use. Leading CISOs and security practitioners on their secure GenAI journey, AIM empowers enterprises to unlock the full potential of GenAI technology without compromising security.

Aireye Dome is the only solution that provides full protection against any form of digital airborne attacks launched against the organizational network. Attacks are automatically blocked and sent to the company SIEM, eliminating the need for platform management and alert chasing. Aireye Dome is a SaaS platform that seamlessly complements your existing network security infrastructure, without the need for architectural changes or messy integrations. For more information, visit: https://www.aireye.tech/

Alkymi transforms enterprise workflows by placing machine learning and automation technology into the hands of business users, turning operational data headaches into a source of efficiency. Alkymi’s core products—Data Inbox and Patterns—allow businesses to extract, analyze, and take action on critical business data in emails and documents. Leading organizations deploy Alkymi to accelerate decision-making, improve customer satisfaction, and empower employees to focus on higher value, rewarding work.

Almanac is how the fastest remote teams work on the Internet, with more structure, more transparency, and fewer meetings. It's the only async all-in-one platform where you can write, approve, organize, and track docs. Whether you're looking to document knowledge, collaborate with teammates, or manage projects, you can do it all on Almanac.

Altscore provides lending infrastructure APIs for lenders, retailers, and SaaS companies to embed and deploy credit products in days. Companies offering credit can leverage our end-to-end Lending-as-a-Service (LaaS) solution to provide capital to their own customers. Existing lenders use any of our LaaS APIs to increase their loan origination rates.

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3). The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at the University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.